Summary The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide
public health and economies has heightened awareness about the lack of effective antiviral …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed millions of
people and continues to cause massive global upheaval. Coronaviruses are positive-strand …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The SARS-CoV-2 virus has infected more than 261 million people and has led to more than
5 million deaths in the past year and a half (https://www. who. org/). Individuals with SARS …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic
impact on human health 1. Widespread community transmission has triggered stringent …

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …

Coronaviruses (CoVs) traffic frequently between species resulting in novel disease
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …

Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the
treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as …